Safety of Nebulized Combination Therapy BromAc® in COVID-19 Respiratory Disease
Status:
Not yet recruiting
Trial end date:
2022-10-30
Target enrollment:
Participant gender:
Summary
COVID-19 has multiple facets including cytokine storm, thromboembolism and gelatinous
secretions. It is known that oxygen exchange is the main problem in patients with COVID-19
and hypoxia is one of the most serious, in which patients succumb to acute respiratory
distress syndrome (ARDS). In other severe respiratory disease such as ventilator associated
pneumonia (VAP), formation of biofilm in the endotracheal tube causes infection to spread to
the lungs, resulting in respiratory decline and high mortality. The development of gelatinous
sputum plugs correlates with negative outcome. Both groups of patients still have limited
therapy options. BromAc is a potent mucolytic, biofilm degrader, cleaves the glycoproteins of
the SARS-CoV-2 virus (antiviral), and down regulates cytokines and chemokine in COVID-19
sputum. The investigators seek to examine the safety and attempt to gain preliminary efficacy
of nebulised BromAc in moderate to severe COVID-19 and other mucus producing, severe,
respiratory diseases.